In a filing, Krystal Biotech Inc revealed its President, R&D Krishnan Suma unloaded Company’s shares for reported $5.5 million on Dec 04 ’25. In the deal valued at $220.16 per share,25,000 shares were sold. As a result of this transaction, Krishnan Suma now holds 1,413,711 shares worth roughly $412.7 million.
Then, Krishnan Suma sold 25,000 shares, generating $5,503,395 in total proceeds. Upon selling the shares at $220.14, the President, R&D now owns 1,483,056 shares.
Before that, Krishnan Krish S sold 25,000 shares. Krystal Biotech Inc shares valued at $5,503,938 were divested by the President and CEO at a price of $220.16 per share. As a result of the transaction, Krishnan Krish S now holds 1,413,711 shares, worth roughly $412.7 million.
Citigroup upgraded its Krystal Biotech Inc [KRYS] rating to a Buy from a a Neutral in a research note published recently. A number of analysts have revised their coverage, including Jefferies’s analysts, who began to cover the stock in early March with a ‘”a Buy”‘ rating. Citigroup also remained covering KRYS and has decreased its forecast on August 06, 2024 with a “Neutral” recommendation from previously “Buy” rating. Goldman started covering the stock on November 20, 2023. It rated KRYS as “a Buy”.
Price Performance Review of KRYS
On Tuesday, Krystal Biotech Inc [NASDAQ:KRYS] saw its stock jump 7.28% to $291.93. Over the last five days, the stock has gained 17.06%. Krystal Biotech Inc shares have risen nearly 90.90% since the year began. Nevertheless, the stocks have risen 18.41% over the past one year.
How much short interest is there in Krystal Biotech Inc?
A steep rise in short interest was recorded in Krystal Biotech Inc stocks on 2025-12-31, dropping by -0.19 million shares to a total of 2.68 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-28 was 2.87 million shares. There was a decline of -7.01%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on October 24, 2023 when Cantor Fitzgerald began covering the stock and recommended ‘”an Overweight”‘ rating along with a $100 price target.
